Thank you. The more licence holders, the more markets, the more sales people, the greater revenue streams. All should, in theory, increase the cashflow depending on the terms of the licence. However, as has been pointed out, there's no EU product yet (awaiting further approvals), US approval has yet to be granted, and there is little by way of product protection. It sounds grim, but it isn't really. There isn't much competition as you know, and none with the same levels of proven clinical efficacy. 8p was easy to spot - the placing was 9p, AIM shares often get spanked to below the placing price, and 8p is roughly the pre-dilution MCAP value of the deal, give or take a smidge. 11p is a sensible uplift from the placing price to reflect the progress made by the company and would be a good base going through the various stages of the first licencing agreement. It wasn't based on any charts, fibonaccis, other TA or anything like that. Given the structure of the warrants, being 15p up to 2019, I'd expect a serious upside from these levels assuming that we get FDA approval, another EU approval, commercial launch, non-EU sales and so on. 15p has to be at a discount to the expected SP in a few years time. It's interesting that the warrants time out within 5 years yet have a 30 day clause in the event of change of control. That says to me that there's a realistic expectation of a sale within 5 years. And that'll do for me. Obviously other opinions exist, this is just mine.
afternoon mate. Have you been accumulating all day?
EarlyBird: the increase in Regent Pacific Group Limited holdings is due to their share of the placing shares, not a recent open market purchase.
waited a while but good price
beaten to it. lol
RP and JM
Looks as if JM is making sure the SP holds up or wants to be the rchest man in the world . It does not matter which one but it does help build confidence in the Company for the long term return
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.